<DOC>
	<DOCNO>NCT00019136</DOCNO>
	<brief_summary>RATIONALE : Interleukin-2 may stimulate person 's white blood cell kill ovarian cancer cell . Interleukin-2 combine white blood cell gene-modified recognize kill ovarian cancer cell may effective treatment recurrent residual ovarian cancer . PURPOSE : Phase I trial study effectiveness interleukin-2 plus gene-modified white blood cell treat patient advanced ovarian epithelial cancer .</brief_summary>
	<brief_title>Gene Therapy Biological Therapy Treating Patients With Ovarian Epithelial Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine clinical response patient advance ovarian epithelial cancer treat intravenously administer allogeneic peripheral blood mononuclear cell-stimulated , gene-modified lymphocyte ( MOv-PBL ) . - Evaluate ability intravenously administer MOv-PBL traffic sit ovarian cancer . - Determine duration survival transduce lymphocyte systemic circulation tumor site patient . OUTLINE : This dose-escalation study . Patients stratified eligibility receive interleukin-2 ( IL-2 ) ( yes v ) . Patients undergo leukapheresis . The collected peripheral blood lymphocyte ( PBLs ) stimulate allogeneic peripheral blood mononuclear cell ( PBMCs ) follow retroviral transduction antiovarian cancer MOv-gamma chimeric receptor gene ( MOv-PBL ) . MOv-PBL reinfused IV 30-60 minute follow IL-2 IV 15-30 minute every 12 hour 8 dos ( eligible ) . This course may repeat least , begin 2-3 week later . Patients receive allogeneic PBMC-stimulated PBLs receive donor PBMCs subcutaneously 1 8 day MOv-PBL infusion instead IL-2 . Cohorts 3-6 patient stratum receive escalating dose MOv-PBL maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . An additional 10 patient receive MOv-PBL , without IL-2 , follow immunization donor PBMCs . Patients follow 4 8 week periodically survival . PROJECTED ACCRUAL : Approximately 13-50 patient accrue study .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven recurrent , resect recurrent , residual ovarian epithelial cancer Failed prior standard effective therapy include cisplatin/carboplatin paclitaxel Tumor positive folatebinding protein monoclonal antibody MOv18 bind Measurable disease CT scan , MRI , ultrasound , physical exam OR Minimal residual disease laparotomy , laparoscopy , peritoneal washing ( i.e. , disease evaluable radiologically physical exam ) PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 0 1 Hematopoietic : WBC great 3,000/mm^3 Platelet count great 100,000/mm^3 Hemoglobin great 9.0 g/dL No coagulation disorder Hepatic : Bilirubin great 2.0 mg/dL Other liver function test less 3 time upper limit normal Hepatitis B antigen negative Renal : Creatinine great 2.0 mg/dL Cardiovascular : No major cardiovascular illness If history ischemic heart disease , congestive heart failure , cardiac arrhythmia , eligible receive interleukin2 Pulmonary : FEV_1 DLCO great 70 % predict No major respiratory illness Immunologic : Must intact immune system evidence positive reaction Candida albicans , mumps , tetanus toxoid skin test standard anergy panel HIV negative No active systemic infection Other : Not pregnant Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : More 2 week since prior biologic therapy Chemotherapy : See Disease Characteristics More 2 week since prior chemotherapy Endocrine therapy : More 2 week since prior endocrine therapy No concurrent steroid Radiotherapy : More 2 week since prior radiotherapy Surgery : See Disease Characteristics Prior debulking allow</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2003</verification_date>
	<keyword>recurrent ovarian epithelial cancer</keyword>
</DOC>